ARVNArvinas, Inc.

$856M

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+22.4% YoY

Gross Profit

$9M100.0% margin

Operating Income

-$47M-508.6% margin

Net Income

-$47M-503.2% margin

EPS (Diluted)

$-0.94

QoQ Revenue Growth

+69.1%

Cash Flow

Operating Cash Flow

$682M

Free Cash Flow

$680M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$787M

Stockholders' Equity

$818M

Cash & Equivalents

$256M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$8M	+22.4%
Gross Profit	$9M	$8M	+22.4%
Operating Income	-$47M	-$32M	-49.0%
Net Income	-$47M	-$31M	-51.9%

ARVN Q3 2021 Earnings — Arvinas, Inc. Revenue & Financial Results | Market Cap Arena